Olympus Canada, a subsidiary of Japanese medical device firm Olympus, has expanded its distribution agreement with EndoClot Plus to include the EndoClot Adhesive in Canada.
The expansion of the distribution partnership follows the commercialisation of the EndoClot portfolio in the US and Europe, the Middle East, and Africa.
The EndoClot Adhesive is a single-use medical device that contains Adhesive Haemostatic Polymer (AHP) and an applicator to seal lesions in the gastrointestinal tract.
AHP is a durable haemostatic polymer resistant to acids and bases in the gastrointestinal tract, and the applicator delivers the synthetic polymer to a lesion.
The haemostatic polymer is recommended for use at the end of procedures to control bleeding, prevent re-bleeding, and protect wounds from irritation.
EndoClot Plus president Stephen Heniges said: “We are very excited to expand our global partnership with Olympus. With Olympus’ support in the US, EMEA, and now in Canada, we expect that more healthcare providers and their patients will be able to benefit from our solutions.”
Queen’s University department of medicine associate professor and gastroenterologist Robert Bechara said: “During EMR and ESD, it’s essential to be able to identify the bleed and treat it at the same time.
“In addition, anything we can do to protect EMR and ESD resection sites and reduce the risk of post-procedural bleeding is key in helping us ensure definitive hemostasis during the recovery period.”
Based in Santa Clara, California, EndoClot Plus is a privately held medical device company specialising in advanced biomaterial therapeutic solutions for gastrointestinal endoscopy.
The company’s technologies align with Olympus’ gastrointestinal endoscopy portfolio.
They support procedures such as endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD).
The procedures are essential for the endoscopic removal of polyps, adenomas, early-stage cancers, and other gastrointestinal mucosal lesions.
With over 100 years of experience, Olympus focuses on enhancing health and safety by supporting the detection, prevention, and treatment of diseases.
Olympus Canada oversees operations and workforce across Canada, including sales, marketing, service, and support functions.
OCI medical business unit vice president Mike Lauzon said: “We are excited to announce our partnership with EndoClot Plus, Inc.
“The addition of their solutions advances our efforts to provide physicians with a full GI portfolio for advanced therapeutic procedures.
“Providing therapeutic solutions for endoscopic resection and associated bleeding management are among Olympus’ core competencies.
“By contributing to safe treatment in GI procedures, we aim to improve patient outcomes and work to elevate the standard of care.”
